PSMA-11
Based on 1 publication(s) in Google Scholar
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize 68Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.61%
- CAS 番号: 1366302-52-4
- 分子式: C44H62N6O17
- 分子量:946.99
-
保管条件:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 PSMA-11
MoreRadionuclide-Drug Conjugates (RDCs) アイソフォーム固有の製品をすべて表示
More
生物活性
|
Other |
[68Ga]Ga-PSMA-11 in vivo imaging[3]:
1. Inject 10-25 MBq of [68Ga]Ga-PSMA-11 into mice bearing LNCaP tumor xenografts via the caudal vein.
2. Anesthetized animals were placed in a small animal PET scanner and a 50-min dynamic microPET scan was recorded starting 1 min after injection, followed by a 20-min static scan.
3. Because [68Ga]Ga-PSMA-11 is rapidly cleared from blood and PSMA-negative tissues, organ and tumor uptake values for [68Ga]Ga-PSMA-11 reflect in vitro data.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 1366302-52-4
-
性状 Solid
-
分子量 946.99
-
分子式 C44H62N6O17
-
Color White to off-white
-
SMILES
OC(CN(CCN(CC(O)=O)CC1=CC(CCC(O)=O)=CC=C1O)CC2=CC(CCC(NCCCCCC(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)=CC=C2O)=O
-
別名
HBED-CC-PSMA
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Imaging Biol
2025 Sep 2. PMID: 40897948
溶剤 & 溶解度
DMSO : 100 mg/mL (105.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Demirci E, et al. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun. 2016 Nov;37(11):1169-79. [Content Brief]
[2]. Eder M, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging[J]. Bioconjugate chemistry, 2012, 23(4): 688-697. [Content Brief]
[3]. Bois F, et al. [68Ga] Ga-PSMA-11 in prostate cancer: a comprehensive review[J]. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10(6): 349. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0560 mL | 5.2799 mL | 10.5598 mL | 26.3994 mL |
| 5 mM | 0.2112 mL | 1.0560 mL | 2.1120 mL | 5.2799 mL | |
| 10 mM | 0.1056 mL | 0.5280 mL | 1.0560 mL | 2.6399 mL | |
| 15 mM | 0.0704 mL | 0.3520 mL | 0.7040 mL | 1.7600 mL | |
| 20 mM | 0.0528 mL | 0.2640 mL | 0.5280 mL | 1.3200 mL | |
| 25 mM | 0.0422 mL | 0.2112 mL | 0.4224 mL | 1.0560 mL | |
| 30 mM | 0.0352 mL | 0.1760 mL | 0.3520 mL | 0.8800 mL | |
| 40 mM | 0.0264 mL | 0.1320 mL | 0.2640 mL | 0.6600 mL | |
| 50 mM | 0.0211 mL | 0.1056 mL | 0.2112 mL | 0.5280 mL | |
| 60 mM | 0.0176 mL | 0.0880 mL | 0.1760 mL | 0.4400 mL | |
| 80 mM | 0.0132 mL | 0.0660 mL | 0.1320 mL | 0.3300 mL | |
| 100 mM | 0.0106 mL | 0.0528 mL | 0.1056 mL | 0.2640 mL |
PSMA-11 関連分類
HY-125399 関連分類
Powered by Bioz